143 related articles for article (PubMed ID: 22735052)
1. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET.
Kung MP; Weng CC; Lin KJ; Hsiao IT; Yen TC; Wey SP
Chang Gung Med J; 2012; 35(3):211-8. PubMed ID: 22735052
[TBL] [Abstract][Full Text] [Related]
2. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
[TBL] [Abstract][Full Text] [Related]
3. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
4. [Molecular imaging of beta-amyloid plaques in the brain].
Ono M
Brain Nerve; 2007 Mar; 59(3):233-40. PubMed ID: 17370649
[TBL] [Abstract][Full Text] [Related]
5. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: novel PET/SPECT imaging probes for diagnosis of Alzheimer's disease.
Ono M; Saji H
J Pharmacol Sci; 2012; 118(3):338-44. PubMed ID: 22382657
[TBL] [Abstract][Full Text] [Related]
6. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
[TBL] [Abstract][Full Text] [Related]
7. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
Gupta HV; Beach TG; Mehta SH; Shill HA; Driver-Dunckley E; Sabbagh MN; Belden CM; Liebsack C; Dugger BN; Serrano GE; Sue LI; Siderowf A; Pontecorvo MJ; Mintun MA; Joshi AD; Adler CH
J Alzheimers Dis; 2021; 80(4):1603-1612. PubMed ID: 33720879
[TBL] [Abstract][Full Text] [Related]
9. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
10. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease.
Liu Y; Zhu L; Plössl K; Choi SR; Qiao H; Sun X; Li S; Zha Z; Kung HF
Nucl Med Biol; 2010 Nov; 37(8):917-25. PubMed ID: 21055622
[TBL] [Abstract][Full Text] [Related]
11. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
12. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
13. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of the radioiodinated imidazo[1,2-a]pyridine derivative DRK092 for amyloid-β imaging in mouse model of Alzheimer's disease.
Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Morimoto Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Suhara T; Higuchi M; Yamada K; Ji B
Neurosci Lett; 2014 Oct; 581():103-8. PubMed ID: 25172571
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled bioactive benzoheterocycles for imaging β-amyloid plaques in Alzheimer's disease.
Yang Y; Cui M
Eur J Med Chem; 2014 Nov; 87():703-21. PubMed ID: 25305715
[TBL] [Abstract][Full Text] [Related]
16. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
18. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
[TBL] [Abstract][Full Text] [Related]
19. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
Macdonald IR; Reid GA; Pottie IR; Martin E; Darvesh S
J Nucl Med; 2016 Feb; 57(2):297-302. PubMed ID: 26541777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
